All baseline cohort parameters, clinical, conventional (knee x-ray and MRI and the robust biochemical markers), and novel markers (T2 relaxation MRI for cartilage collagen distribution, gagCEST MRIcartilage for proteoglycan content, knee CT/x-ray for bone shape and trabecular architecture, knee motion, and novel biochemical markers describing turnover of specific tissue component, as well as involvement of hand, hip and spine joint damage, hand joint inflammation, hip motion and shape and bone architecture) will be used to identify (a set of) predictors that can discriminate between the knee OA progressors and (paired) non-progressors within a specific phenotype.

Primary Purpose
Define subsets of (phenotypically) different patients in both the existing cohorts as well as (later) in the new longitudinal extension cohorts and subsequently identify the “right patient” to treat for each subset/phenotype via innovative stratification techniques.
Study Types
observational biomarker validation and qualification
Description of Cohorts
Cohort will also include age-matched healthy controls as well as end-stage established OA patients assigned to ‘dominant’ progressive subclasses of clinically defined knee osteoarthritis with potential involvement of hip and/or hand OA with each a paired non-progressive knee OA phenotype
Informed Consent Given?
Multi-center Study?
Homo sapiens
Number of subjects
knee osteoarthritis osteoarthritis
Type of Samples Collected
Blood Serum
Age Range of Study Participants
BMI Range of Study Participants